111 Capital Reduces Stock Position in Apellis Pharmaceuticals, Inc. $APLS

111 Capital cut its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 26.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 12,400 shares of the company’s stock after selling 4,436 shares during the period. 111 Capital’s holdings in Apellis Pharmaceuticals were worth $215,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Assetmark Inc. grew its position in shares of Apellis Pharmaceuticals by 3,938.7% in the first quarter. Assetmark Inc. now owns 1,252 shares of the company’s stock valued at $27,000 after purchasing an additional 1,221 shares in the last quarter. Parallel Advisors LLC grew its position in shares of Apellis Pharmaceuticals by 80.0% in the second quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock valued at $33,000 after purchasing an additional 855 shares in the last quarter. GF Fund Management CO. LTD. grew its position in shares of Apellis Pharmaceuticals by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company’s stock valued at $70,000 after purchasing an additional 573 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Apellis Pharmaceuticals by 15.6% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,855 shares of the company’s stock valued at $84,000 after purchasing an additional 655 shares in the last quarter. Finally, Legacy Capital Group California Inc. grew its position in shares of Apellis Pharmaceuticals by 32.8% in the first quarter. Legacy Capital Group California Inc. now owns 9,554 shares of the company’s stock valued at $209,000 after purchasing an additional 2,359 shares in the last quarter. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on APLS shares. Royal Bank Of Canada upped their price target on Apellis Pharmaceuticals from $17.00 to $19.00 and gave the company a “sector perform” rating in a research report on Friday, August 1st. Raymond James Financial lowered their price objective on Apellis Pharmaceuticals from $52.00 to $50.00 and set an “outperform” rating for the company in a research report on Friday, August 1st. Robert W. Baird increased their price objective on Apellis Pharmaceuticals from $47.00 to $50.00 and gave the stock an “outperform” rating in a research report on Friday, July 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Apellis Pharmaceuticals in a research report on Saturday, September 27th. Finally, Cantor Fitzgerald increased their price objective on Apellis Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $33.29.

Apellis Pharmaceuticals Stock Up 3.5%

NASDAQ:APLS opened at $25.21 on Wednesday. The company has a quick ratio of 3.16, a current ratio of 3.77 and a debt-to-equity ratio of 2.90. The stock’s fifty day moving average is $25.15 and its two-hundred day moving average is $21.11. Apellis Pharmaceuticals, Inc. has a 52 week low of $16.10 and a 52 week high of $35.72. The stock has a market capitalization of $3.18 billion, a price-to-earnings ratio of -13.85 and a beta of 0.69.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Thursday, July 31st. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.11. Apellis Pharmaceuticals had a negative return on equity of 116.09% and a negative net margin of 30.24%.The company had revenue of $171.39 million for the quarter, compared to analysts’ expectations of $187.91 million. During the same period in the prior year, the firm earned ($0.30) earnings per share. The firm’s revenue was down 10.6% compared to the same quarter last year. Research analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Activity

In other news, Director A. Sinclair Dunlop sold 31,092 shares of the stock in a transaction on Friday, September 19th. The stock was sold at an average price of $22.95, for a total value of $713,561.40. Following the sale, the director directly owned 68,908 shares in the company, valued at approximately $1,581,438.60. This trade represents a 31.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel David O. Watson sold 5,000 shares of the stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $24.34, for a total value of $121,700.00. Following the completion of the sale, the general counsel owned 118,730 shares in the company, valued at approximately $2,889,888.20. The trade was a 4.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 430,919 shares of company stock worth $10,656,945. Corporate insiders own 6.80% of the company’s stock.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).